序贯疗法联合益生菌对幽门螺杆菌疗效的meta分析

doi:10.3760/cma.j.issn.1007-1245.2023.24.014

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (24): 3590-3598.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.014

序贯疗法联合益生菌对幽门螺杆菌疗效的meta分析

谢嘉欣¹ 刁德昌² 魏琳³ 刘杨晨³ 谭萍² 尤久红² 隆丽芳⁴ 谢湘萁¹ 朱鑫鑫⁴ 林美珍³

¹广州中医药大学第二临床医学院，广州　510405；²广东省中医院胃肠肿瘤中心，广州　510120；³广东省中医院护理部，广州　510120；⁴湖南中医药大学护理学院，长沙　410208

收稿日期:2023-08-14 出版日期:2023-12-15 发布日期:2024-01-04
通讯作者: 林美珍，Email：lmzmay@163.com
基金资助:
广州市科技计划项目（202002030436、202102010240）；广东省中医院中医药科学技术研究专项（YN2022HL.01）

Sequential therapy combined with probiotics for helicobacter pylori: a meta-analysis

Xie Jiaxin¹, Diao Dechang², Wei Lin³, Liu Yangchen³, Tan Ping², You Jiuhong², Long Lifang⁴, Xie Xiangqi¹, Zhu Xinxin⁴, Lin Meizhen³

¹Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China; ²Gastrointestinal Tumor Center, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China; ³Department of Nursing, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China; ⁴College of Nursing, Hunan University of Traditional Chinese Medicine, Changsha 410208, China

Received:2023-08-14 Online:2023-12-15 Published:2024-01-04
Contact: Lin Meizhen, Email: lmzmay@163.com
Supported by:
Project of Plan of Science and Technology in Guangzhou (202102010240 and 202002030436); Special Project of Science and Technology of Chinese Medicine at Guangdong Provincial Hospital of Traditional Chinese Medicine (YN2022HL.01)

摘要/Abstract

摘要：

目的　系统评价序贯疗法联合益生菌治疗幽门螺杆菌（Helicobacter pylori，Hp）感染的疗效和安全性。方法　检索从建库至2022年6月20日采用序贯疗法联合益生菌治疗Hp感染的随机对照试验研究，根据纳排标准筛选文献，用改良版Jadad量表进行偏倚风险的评价，采用RevMan 5.3软件进行统计与分析。结果　共纳入22项随机对照试验研究，总计3 158例患者。Meta分析结果显示：序贯疗法联合益生菌治疗Hp感染总转阴率（OR=3.99，95%CI 3.10～5.14，P<0.001）、有效率（OR=4.98，95%CI 3.57～6.94，P<0.001）、复发率（OR=0.20，95%CI 0.07～0.56，P=0.002）、症状积分（OR=-1.41，95%CI -1.51～-1.31，P<0.001）、不良反应率（OR=0.28，95%CI 0.21～0.36，P<0.001）均优于单纯序贯疗法。结论　与单纯序贯疗法治疗Hp感染相比，序贯疗法联合益生菌治疗Hp感染的转阴率和有效率更高，症状积分、复发率、不良反应发生率更低。

关键词:

序贯疗法, 益生菌, 幽门螺杆菌感染, 不良反应, meta分析

Abstract:

Objective　To systematically evaluate the efficacy and safety of sequential therapy combined with probiotics in the treatment of Helicobacter pylori (Hp) infection. Methods　The randomized controlled trials of sequential therapy combined with probiotics in the treatment of Hp infection were retrieved from the establishment to June 20, 2022. The literatures were screened according to the inclusion criteria. The modified Jadad scale was used to evaluate the bias risk. The RevMan5.3 software was used for the statistics and analysis. Results　A total of 22 randomized controlled trials involving 3 158 patients were included. Meta-analysis results showed that the total negative conversion rate (OR=3.99, 95%CI 3.10-5.14, P < 0.001), effective rate (OR=4.98, 95%CI 3.57-6.94, P<0.001), recurrence rate (OR=0.20, 95%CI 0.07-0.56, P=0.002), symptom score (OR=-1.41, 95%CI -1.51--1.31, P<0.001 ), and incidence of adverse reactions (OR=0.28, 95%CI 0.21-0.36, P<0.001) of sequential therapy combined with probiotics in the treatment of Hp infection were better than those of the control group. Conclusion　The negative conversion rate and effective rate of sequential therapy combined with probiotics in the treatment of Hp infection are higher than those of the simple sequential therapy, and the symptom score, recurrence rate, and incidence of adverse reactions are lower.

Key words:

Sequential therapy, Probiotics, Helicobacter pylori infection, Adverse reactions, Meta-analysis

谢嘉欣刁德昌魏琳刘杨晨谭萍尤久红隆丽芳谢湘萁朱鑫鑫林美珍.

序贯疗法联合益生菌对幽门螺杆菌疗效的meta分析 [J]. 国际医药卫生导报, 2023, 29(24): 3590-3598.

Xie Jiaxin, Diao Dechang, Wei Lin, Liu Yangchen, Tan Ping, You Jiuhong, Long Lifang, Xie Xiangqi, Zhu Xinxin, Lin Meizhen.

Sequential therapy combined with probiotics for helicobacter pylori: a meta-analysis [J]. International Medicine and Health Guidance News, 2023, 29(24): 3590-3598.

参考文献

[1] Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter pylori infection: optimization strategies in a high resistance era[J]. Expert Opin Pharmacother, 2015,16(15):2307-2317.DOI:10.1517/14656566.2015.1084503.
[2] Chang YL, Tung YC, Tu YK, et al. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis[J]. BMJ Open Gastroenterol, 2020,7(1):e000472. DOI: 10.1136/bmjgast-2020-000472.
[3] 国家消化系疾病临床医学研究中心上海,国家消化道早癌防治中心联盟(GECA),中华医学会消化病学分会幽门螺杆菌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华消化杂志,2019,39(5):310-316.DOI:10.3760/cma.j.issn.0254-1432.2019.05.008.
[4] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,刘文忠,谢勇,等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2017,22(6):346-360.DOI:10.3969/j.issn.1008-7125.2017.06.006.
[5] De Francesco V, Zullo A, Manta R, et al. First-line therapies for H. pylori infection in Italy: a pooled-data analysis[J]. Acta Gastroenterol Belg, 2022,85(2):295-299. DOI: 10.51821/85.2.9680.
[6] Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: where are we now?[J]. J Gastroenterol Hepatol, 2016,31(12):1918-1926. DOI: 10.1111/jgh.13418.
[7] Zagari RM, Frazzoni L, Marasco G, et al. Treatment of Helicobacter pylori infection: a clinical practice update[J]. Minerva Med, 2021,112(2):281-287. DOI: 10.23736/S0026-4806.20.06810-X.
[8] 刘媛媛.益生菌、序贯疗法联合使用对胃炎(Hp相关)的治疗效果观察[J].特别健康,2021(24):102-103.
[9] 孙翠凤.益生菌联合序贯疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎的临床效果分析[J].中国保健营养,2021,31(35):46.
[10] 杨茜.益生菌、序贯疗法联合使用对胃炎(Hp相关)的治疗效果观察[J].健康必读,2021(30):116-117.
[11] 赵晓佳,翟华丽,李一鸣,等.双歧杆菌乳杆菌三联活菌联合改良序贯疗法治疗HP阳性慢性萎缩性胃炎的疗效与安全性[J].海南医学,2021,32(4):442-445.DOI:10.3969/j.issn.1003-6350.2021.04.009.
[12] 郑涛.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J].饮食保健,2021(9):67.
[13] 李小飞,祁会娟.双歧杆菌四联活菌片辅助治疗HP阳性消化性溃疡患儿的效果分析[J].医药论坛杂志,2021,42(18):17-21.
[14] 庄丽娜.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J].家有孕宝,2020,2(13):136.
[15] 葛琦.益生菌联合序贯疗法治疗幽门螺杆菌相关性胃炎的临床疗效[J].系统医学,2019,4(18):56-58.DOI:10.19368/j.cnki.2096-1782.2019.18.056.
[16] 李贤辉.益生菌联合序贯疗法治疗幽门螺杆菌相关性胃炎的临床研究[J/CD].世界最新医学信息文摘(连续型电子期刊),2019,19(46):209,211.DOI:10.19613/j.cnki. 1671-3141.2019.46.123.
[17] 石巍.序贯疗法联合双歧杆菌三联活菌胶囊治疗幽门螺杆菌阳性消化性溃疡的临床观察[J].中国医药科学,2019,9(23):257-259,273.DOI:10.3969/j.issn.2095-0616. 2019.23.079.
[18] 史丽颖.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J/CD].临床医药文献电子杂志,2019,6(89):38-39.DOI:10.16281/j.cnki.jocml.2019.89.023.
[19] 杜玉芬.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J].健康之友,2018(16):171,164.
[20] 高翠萍.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J].中国保健营养,2018,28(25):165.DOI:10.3969/j.issn.1004-7484.2018.25.243.
[21] 何爱凤.益生菌、序贯疗法联合使用对幽门螺杆菌相关性胃炎的治疗效果观察[J].心理医生,2018,24(35):356.
[22] 李苗琼,许江兰.幽门螺杆菌相关性慢性萎缩性胃炎经益生菌结合序贯疗法治疗的效果与安全性探讨[J].中外医学研究,2018,16(35):151-153.DOI:10.14033/j.cnki.cfmr. 2018.35.072.
[23] 王丽梅.益生菌联合序贯疗法治疗幽门螺杆菌相关性胃炎的临床研究[J/CD].临床医药文献电子杂志,2018,5(29):19,22.DOI:10.3877/j.issn.2095-8242.2018.29.012.
[24] 杜三军,温杰,张娅娟,等.改良序贯疗法联合微生态制剂、单纯改良序贯疗法、标准三联疗法治疗幽门螺杆菌感染的对照研究[J].中国基层医药,2015,22(13):1956-1958,1959.DOI:10.3760/cma.j.issn.1008-6706.2015.13.013.
[25] 甘伙烨,覃喜香,彭铁立,等.序贯疗法和加用益生菌对幽门螺杆菌感染的疗效观察[J].中国实用医药,2014,9(10):28-29,30.
[26] 谢丽华,胡红松,谭朝晖,等.益生菌联合序贯疗法治疗幽门螺杆菌相关性慢性萎缩性胃炎96例的疗效分析[J].广西医学,2013,(7):914-916.DOI:10.11675/j.issn.0253-4304. 2013.07.38.
[27] Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy[J]. Helicobacter, 2012,17(4):254-263. DOI: 10.1111/j.1523-5378.2012.00944.x.
[28] Çekin AH, Şahintürk Y, Akbay Harmandar F, et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance[J]. Turk J Gastroenterol, 2017,28(1):3-11. DOI: 10.5152/tjg.2016.0278.
[29] Seddik H, Boutallaka H, Elkoti I, et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial[J]. Eur J Clin Pharmacol, 2019,75(5):639-645. DOI: 10.1007/s00228-019-02625-0.
[30] Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol, 2022,28(12):1187-1203. DOI: 10.3748/wjg.v28.i12.1187.
[31] Rowland M. The continuing decline in the prevalence of Helicobacter pylori infection[J]. Lancet Child Adolesc Health, 2022,6(3):139-140. DOI: 10.1016/S2352-4642(22)00026-8.
[32] Sijmons D, Guy AJ, Walduck AK, et al. Helicobacter pylori and the role of lipopolysaccharide variation in innate immune evasion[J]. Front Immunol, 2022,13:868225. DOI: 10.3389/fimmu.2022.868225.
[33] Fang Y, Xie H, Fan C. Association of hypertension with helicobacter pylori: a systematic review and meta-analysis[J]. PLoS One, 2022,17(5):e0268686. DOI: 10.1371/journal.pone.0268686.
[34] Zhu L, Huang Y, Li H, et al. Helicobacter pylori promotes gastric cancer progression through the tumor microenvironment[J]. Appl Microbiol Biotechnol, 2022,106(12):4375-4385. DOI: 10.1007/s00253-022-12011-z.
[35] Guo Y, Cao XS, Guo GY, et al. Effect of Helicobacter Pylori eradication on human gastric microbiota: a systematic review and meta-analysis[J]. Front Cell Infect Microbiol, 2022,12:899248. DOI: 10.3389/fcimb.2022.899248.
[36] 王文玲,宋晓梅,赵玲.幽门螺杆菌感染的危险因素及相关护理干预对策研究[J].国际医药卫生导报,2020,26(8):1161-1164.DOI:10.3760/cma.j.issn.1007-1245.2020.08.040.
[37] Zullo A, Fiorini G, Scaccianoce G, et al. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?[J]. J Gastrointestin Liver Dis, 2019,28(1):11-14. DOI: 10.15403/jgld.2014.1121.281.hpy.
[38] Razavizadeh M, Arj A, Madani M, et al. Comparing the efficacy of sequential and standard quadruple therapy for eradication of H. Pylori infection[J]. Acta Medica (Hradec Kralove), 2020,63(4):183-187. DOI: 10.14712/18059694.2020.61.
[39] Zhou Y, Ye Z, Wang Y, et al. Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children[J]. Helicobacter, 2021,26(4):e12809. DOI: 10.1111/hel.12809.
[40] Viazis N, Argyriou K, Kotzampassi K, et al. A four-probiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates[J]. Nutrients, 2022,14(3):632. DOI: 10.3390/nu14030632.
[41] Huang R, Wu F, Zhou Q, et al. Lactobacillus and intestinal diseases: mechanisms of action and clinical applications[J]. Microbiol Res, 2022,260:127019. DOI: 10.1016/j.micres.2022.127019.
[42] Zhang M, Zhang C, Zhao J, et al. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects[J]. Microb Pathog, 2020,147:104403. DOI: 10.1016/j.micpath.2020.104403.
[43] Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis[J]. Medicine (Baltimore), 2019,98(15):e15180. DOI: 10.1097/MD.0000000000015180.
[44] Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections[J]. BMC Gastroenterol, 2021,21(1):388. DOI: 10.1186/s12876-021-01977-1.
[45] Ji J, Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy[J]. Int J Mol Sci, 2020,21(3):1136. DOI: 10.3390/ijms21031136.
[46] Zhou BG, Chen LX, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis[J]. Helicobacter, 2019,24(5):e12651. DOI: 10.1111/hel.12651.
[47] O'Connor A, Fischbach W, Gisbert JP, et al. Treatment of Helicobacter pylori infection 2016[J]. Helicobacter, 2016,21 Suppl 1:55-61. DOI: 10.1111/hel.12342.
[48] Zamani M, Alizadeh-Tabari S, Zamani V, et al. Worldwide and regional efficacy estimates of first-line Helicobacter pylori treatments: a systematic review and network meta-analysis[J]. J Clin Gastroenterol, 2022,56(2):114-124. DOI: 10.1097/MCG.0000000000001641.
[49] Moradniani M, Mirbeik-Sabzevari Z, Jaferian S, et al. Levofloxacin based vs clarithromycin based sequential therapy in helicobacter pylori eradication; a randomized clinical trial[J]. Gastroenterol Hepatol Bed Bench, 2018 ,11(1):19-26.
[50] Zullo A, De Francesco V, Vaira D. Sequential therapy for Helicobacter pylori eradication: is levofloxacin better?[J]. Gut, 2011,60(11):1604; author reply 1605-1606. DOI: 10.1136/gut.2010.231233.
[51] Lee H, Hong SN, Min BH, et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea[J]. Dig Liver Dis, 2015,47(2):114-118. DOI: 10.1016/j.dld.2014.10.014.
[52] 姜琦,陈林,王静,赵昌杰,等.含左氧氟沙星的三联疗法及序贯疗法与传统序贯疗法治疗幽门螺杆菌的疗效比较[J].南京医科大学学报(自然科学版),2010,30(10):1439-1441,1444.
[53] Eslami M, Yousefi B, Kokhaei P, et al. Are probiotics useful for therapy of Helicobacter pylori diseases?[J]. Comp Immunol Microbiol Infect Dis, 2019,64:99-108. DOI: 10.1016/j.cimid.2019.02.010.
[54] He C, Kong F, Chai X, et al. Effect of probiotic-assisted eradication of cagA+/vacA s1m1 Helicobacter pylori on intestinal flora[J]. Biomed Res Int, 2022,2022:8607671. DOI: 10.1155/2022/8607671.
[55] Chen MJ, Chen CC, Huang YC, et al. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial[J]. Helicobacter, 2021,26(6):e12857. DOI: 10.1111/hel.12857.
[56] Compare D, Sgamato C, Nardone OM, et al. Probiotics in gastrointestinal diseases: all that glitters is not gold[J]. Dig Dis, 2022,40(1):123-132. DOI: 10.1159/000516023.

序贯疗法联合益生菌对幽门螺杆菌疗效的meta分析

Sequential therapy combined with probiotics for helicobacter pylori: a meta-analysis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	武琰娇陈丽萍侯怀晶徐紫清张凌云. 益生菌治疗轻度认知障碍和阿尔茨海默病患者的有效性及安全性 [J]. 国际医药卫生导报, 2024, 30(1): 1-7.
[2]	赵怡迪梁好陈木欣魏琳. 身体成分与衰弱发生风险关系的meta分析 [J]. 国际医药卫生导报, 2024, 30(1): 8-14.
[3]	柯金王恒石张善兰. 卡瑞利珠单抗免疫相关不良反应临床分析 [J]. 国际医药卫生导报, 2023, 29(9): 1258-1262.
[4]	熊愉梅左露露黄雅楠. 慢性疾病静脉采血体检者采血不良反应研究 [J]. 国际医药卫生导报, 2023, 29(9): 1327-1331.
[5]	戚燕芝张艳丽. 左氧氟沙星注射液致严重呃逆、呕吐1例 [J]. 国际医药卫生导报, 2023, 29(7): 1002-1004.
[6]	赵战威崔红霞. 荜铃胃痛颗粒致消化系统反应的分析与思考 [J]. 国际医药卫生导报, 2023, 29(7): 1004-1006.
[7]	郭闪闪李志鹏张颖. 针刺联合经颅磁刺激对脑梗死合并帕金森综合征患者的疗效 [J]. 国际医药卫生导报, 2023, 29(5): 642-646.
[8]	吴艳萍戚留英. 碘克沙醇致过敏性休克1例 [J]. 国际医药卫生导报, 2023, 29(5): 692-694.
[9]	陈晶晶王栓铎. 中药辅助肠外营养对胃癌患者术后机体营养状态的影响 [J]. 国际医药卫生导报, 2023, 29(4): 492-496.
[10]	何祥琴张军华杨芳丁国锋. 蒲元和胃胶囊致急性重度肝损伤1例 [J]. 国际医药卫生导报, 2023, 29(22): 3205-3208.
[11]	李浩李江涛刘丹李顺华. 贝利尤单抗治疗系统性红斑狼疮患者的疗效及安全性的meta分析 [J]. 国际医药卫生导报, 2023, 29(22): 3217-3224.
[12]	谢燕陈玉莹江锦鸿. ROMA指数在卵巢癌诊断中临床价值的meta分析 [J]. 国际医药卫生导报, 2023, 29(22): 3224-3230.
[13]	丁雪邹丽峰许军焦烨. 胸椎旁神经阻滞联合全麻对胸腔镜肺癌根治术患者炎症反应及免疫功能的影响 [J]. 国际医药卫生导报, 2023, 29(21): 3030-3034.
[14]	卫莎林文涛赵婷婷牛艳妮张妮娜. 托法替布联合艾拉莫德治疗类风湿关节炎的效果及对细胞免疫功能的影响 [J]. 国际医药卫生导报, 2023, 29(20): 2883-2886.
[15]	李闪珊梁冰刘其伟. 托烷司琼与艾司奥美拉唑防治结直肠癌患者化疗相关胃肠道不良反应的应用研究 [J]. 国际医药卫生导报, 2023, 29(18): 2592-2596.